FDA comments on phase I clinical trials without vector biodistribution data

@article{Epstein1999FDACO,
  title={FDA comments on phase I clinical trials without vector biodistribution data},
  author={Suzanne Epstein and Steven Bauer and A. E. Miller and Anne M. Pilaro and Philip D. Noguchi},
  journal={Nature Genetics},
  year={1999},
  volume={22},
  pages={326-326}
}
326 nature genetics • volume 22 • august 1999 hood estimate of linkage disequilibrium D (ref. 5) was 0.71 (P<0.005), confirming the presence of moderate to strong linkage disequilibrium between the 2 variant sites. It is unlikely that the 5569A polymorphism has functional significance, because it is found within intron 4 and does not disrupt a splice-site consensus sequence. Moreover, all 5474A/5569A compound heterozygotes had a transferrin saturation in the normal range (mean 31%, range 20–40… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
3 Citations
0 References
Similar Papers